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High-dose melphalan 200 mg/m2 (MEL 200) is the standard of care as a conditioning regimen for autologous
hematopoietic stem cell transplantation (AHSCT) for multiple myeloma (MM). We compared a novel con-
ditioning combination incorporating busulfan, melphalan, and bortezomib (BUMELVEL) versus standard MEL
200 in newly diagnosed patients undergoing AHSCT for MM. Between July 2009 and May 2012, 43 eligible
patients received BUMELVEL conditioning followed by AHSCT. BU was administered i.v. daily for 4 days to
achieve a target area under the concentration-time curve total of 20,000 mM$min based on pharmacokinetic
analysis after the ﬁrst dose. MEL 140 mg/m2 (MEL 140) and VEL 1.6 mg/m2 were administered i.v. on days 2
and 1, respectively. Outcomes were compared with a contemporaneous North American cohort (n ¼ 162)
receiving MEL 200 matched for age, sex, performance status, stage, interval from diagnosis to AHSCT, and
disease status before AHSCT. Multivariate analysis of relapse, progression-free survival (PFS), and overall
survival (OS) was performed. The median follow-up was 25 months. No transplant-related mortality was
observed in the study cohort at 1 year. PFS at 1 year was superior in the BUMELVEL cohort (90%) in com-
parison with 77% in MEL 200 historical control subjects (P ¼ .02). Cumulative incidence of relapse was lower
in the BUMELVEL group versus the MEL 200 group (10% at 1 year versus 21%; P ¼ .047). OS at 1 year was
similar between cohorts (93% versus 93%; P ¼ .89). BU can be safely combined with MEL 140 and VEL without
an increase in toxicities or transplant-related mortality. We observed a superior PFS in the BUMELVEL cohort
without maintenance therapy, warranting further trials.
 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).INTRODUCTION introduction of novel agents such as proteasome inhibitors
High-dose chemotherapy followed by autologous he-
matopoietic stem cell transplantation (AHSCT) is an effective
therapy for transplant-eligible patients as consolidation after
induction therapy in newly diagnosed multiple myeloma
(MM). The beneﬁt of AHSCT also extends to patients with
relapsed disease who remain transplant eligible. The effec-
tiveness of AHSCT for patients with MM remains relevant
despite signiﬁcant therapeutic advances achieved with thedgments on page 1395.
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ty for Blood and Marrow Transplantation. Publi
g/licenses/by-nc-nd/4.0/).and immunomodulatory agents. MM remains the most
common indication for AHSCT in North America and Europe
[1]. Single-agent melphalan, at a dose of 200 mg/m2 (MEL
200), is the international standard for conditioning before
AHSCT for MM [2]. Other chemotherapy and chemo-
radiotherapy regimens have been used in preparation for
AHSCT but with no clear superiority over MEL 200 [3]. These
other combination regimens are generally associated with
increased hematologic and nonhematologic toxicities
without improvement in efﬁcacy.
High-dose busulfan (BU) and melphalan (MEL) are mye-
loablative chemotherapeutic agents. Both are effective and
well-tolerated agents that have been used for over 20 years
in MM and other malignancies as conditioning regimens forshed by Elsevier Inc. This is an open access article under the CC BY-NC-ND
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superior progression-free survival (PFS) compared with MEL
200 in patients who had not achieved European Group for
Blood and Marrow Transplantation criteria (CR) before
AHSCT [4,5]. Additionally, the combination of bortezomib
(VEL) andMEL appears to be synergistic, especially when VEL
is administered after MEL 200 [6].
We prospectively evaluated a conditioning regimen con-
sisting of high-dose i.v. BU and MEL followed by VEL
(BUMELVEL) in an open-label, phase I/II fashion aimed at
improving PFS after AHSCT for MM patients. A predeﬁned
maximum tolerated dose was used in this trial and consisted
of BU 130 mg/m2 daily for 4 days and adjusted to achieve a
target area under the concentration-time curve (AUC) total of
20,000 mM$min, MEL 140 mg/m2, and VEL 1.6 mg/m2. We
then compared the results of patients who received the
predeﬁned maximum tolerated dose against a contempora-
neousmatched cohort of patients with similar characteristics
who received single-agent MEL 200.METHODS
Between July 2009 and May 2012, 43 patients received BUMELVEL
conditioning followed by AHSCT in a single-center, open-label phase I/II
protocol. Inclusion criteria included adults with MMwho had a creatinine of
less than 2.5 mg/dL, without active infections or severe obstructive and/or
restrictive pulmonary disease determined by pulmonary function testing
(ie, DLCO < 50% and/or FEV1 < 50% and/or FVC < 50%) and cardiac ejection
fraction greater than 40%. Response criteria were assessed according to the
International Myeloma Working Group Uniform Response Criteria [7].
Neutrophil and platelet engraftment were deﬁned as the ﬁrst of 3 days
with a neutrophil count > .5  109/L and ﬁrst date of 3 consecutive labo-
ratory values with an untransfused platelet count  20  109/L. Because BU
has been associated with the risk of sinusoidal obstructive syndrome (SOS),
wemonitored for SOS using the Baltimore diagnostic criteria [8]. It is known
that SOS risk is higher when the total BU AUC exceeds 24,000 mM$min [9].
Therefore, BU was administered i.v. daily for a total of 4 days with the ﬁrst
2 days (days6 and 5) at ﬁxed dose of 130 mg/m2 over 3 hours and the
subsequent 2 doses (days 4 and 3) adjusted to achieve a target AUC total
of 20,000 mM$min determined by pharmacokinetic analysis after the ﬁrst
dose of i.v. BU. MEL 140 mg/m2 and VEL 1.6 mg/m2 were administered i.v. on
days 2 and 1, respectively.
Patients received prophylaxis for oral mucositis with palifermin: 2 doses
of 6.25 mg were administered by i.v. bolus injection for 2 consecutive days
before the ﬁrst BU dose (days 8 and 7), and a third dose of 6.25 mg was
administered on day 0 after stem cell infusion. This study was approved by
the Loyola University Chicago Stritch School of Medicine Institutional Re-
view Board, and all patients voluntarily signed informed consent.STUDY DESIGN
Data from this phase I/II clinical trial in MM patients transplanted at
Loyola University Chicago Medical Center using the BUMELVEL conditioning
regimen were compared against a matched control cohort of contempora-
neous North AmericanMMpatients (n¼ 162) receiving single-agent MEL 200
conditioning. Only patients who received the predeﬁned maximum tolerated
dose were included in the comparison analysis. The control subjects were
identiﬁed from the Center for International Blood and Marrow Transplant
Research (CIBMTR) database. The comparison was done on a 1:3 match
(Loyola-to-CIBMTR). Control subjects were randomly selected andmatched by
age, sex, Karnofsky performance status (KPS), disease stage, interval from
diagnosis to AHSCT, and disease status before AHSCT. Fifty-four centers, not
including the study center, contributed with patients for the control group.
Multivariate analysis of relapse, PFS, and overall survival (OS) was performed.
Maintenance therapy was not administered to patients or control subjects.Control Cohort Database
The CIBMTR is a research afﬁliation of the International Bone Marrow
Transplant Registry and the National Marrow Donor Program (NMDP) and
receives data from over 500 transplantation centers worldwide on allogeneic
and autologous hematopoietic stem cell transplantation. Data are submitted
to the Statistical Center at the Medical College of Wisconsin in Milwaukee
and the NMDP Coordinating Center in Minneapolis, where computerized
checks for discrepancies, physicians’ reviews of submitted data, and on-site
audits of participating centers ensure data quality. Observational studiesconducted by the CIBMTR are performed with approval of the institutional
review boards of the NMDP and the Medical College of Wisconsin.
Statistical Analysis
The primary endpoint of the study was the 1-year PFS after a myeloa-
blative preparative regimen consisting of i.v. BUMELVEL versus MEL 200.
Using a 1:3 match comparison, the study included 43 patients on the
BUMELVEL regimen and 162 patients from the CIBMTR database. Descriptive
statistics were used to report results including demographics, disease-
related factors, transplant-related factors, incidence and severity of muco-
sitis, incidence and severity of SOS, remission rates, and relapse rates.
Survival analysis was done using a Cox proportional hazards regression to
adjust for differences between the groups. P values were always 2-tailed and
considered signiﬁcant when <.05.
Medians and ranges are listed for continuous variables. The total num-
ber of patients and the percentage of each subgroup were calculated for
categorical variables. Characteristics of patients in the 2 study cohorts were
compared using the Mann-Whitney-Wilcoxon test for continuous variables
and chi-square test for discrete variables. For discrete variables with small
group size, the Fisher’s exact testwas used for comparison. Probability of PFS
and OS was calculated using the Kaplan-Meier estimator, with the variance
estimated by the Greenwood’s formula. Probabilities of treatment-related
mortality (TRM) and relapse were generated using cumulative incidence
estimates to accommodate the competing risk event. The point-wise com-
parison was used to analyze outcomes of 2 study cohorts. All tests were 2-
sided with a signiﬁcant level of .05.
Multivariate analysis of TRM, relapse, PFS, and OS were performed using
Cox proportional hazards regression models. The variables considered in the
multivariable were preparative regimen, age, gender, KPS, isotype, inter-
national stage for MM, Mayo risk stratiﬁcation at diagnosis, number of prior
chemotherapy regimens before transplantation, chemotherapy regimens
before transplantation, disease status before transplantation, time from
diagnosis to transplantation, and year of transplantation. The assumption of
proportional hazards for each factor in the Coxmodel was tested using time-
dependent covariates. A backward stepwise model selection approach was
used to identify all signiﬁcant risk factors. Each step of model building
contained the main effect for 2 different regimens. Factors signiﬁcant at a 5%
level were kept in the ﬁnal model. The potential interactions between main
effects and all signiﬁcant risk factors were tested.
RESULTS
Patient Characteristics
Both cohorts were balanced for age, gender, KPS, MM
isotypes, time from diagnosis to transplantation, disease
stage, and disease status before transplantation (Table 1).
Patient demographics in the BUMELVEL and MEL 200 groups
included the following: median age 62 years and 61 years,
respectively; KPS  90% in 74% and 75%, respectively; and
chemotherapy-sensitive disease before transplantation in
95% and 91%, respectively. All patients underwent AHSCT
within 12 months from diagnosis.
Of note, the MEL 200 control cohort had more standard-
risk patients per Mayo Stratiﬁcation of Myeloma and Risk-
Adapted Therapy (mSMART) [10] (78% versus 40% in
BUMELVEL, P < .0001) and more patients with only 1 prior
line of therapy pre-AHSCT (67% versus 47%, P ¼ .02). Patients
in the BUMELVEL group had received induction combination
regimens involving VEL, lenalidomide, and dexamethasone
(51%); VEL and dexamethasone (35%); or VEL, thalidomide,
and dexamethasone (14%) before AHSCT. At the time of
transplantation, 3 (7%) and 15 (35%) patients were in CR and
very good partial remission (VGPR), respectively. Median
follow-up for the BUMELVEL and MEL 200 cohorts were
25 months and 35months, respectively. Sixty-two percent of
the control group received VEL either as a doublet or in
combination with thalidomide or lenalidomide. Thirty-six
percent received induction therapy with other novel agents
consisting of doublets with thalidomide or lenalidomide.
Outcomes
The BUMELVEL regimen resulted in an overall response
rate of 98%, including at least VGPR in 70% and CR in 42%
Table 1
Characteristics of Patients Who Underwent Single Autologous Transplant
with i.v. BU, MEL Followed by VEL and High-Dose MEL between 2009
and 2012
Characteristics BUMELVEL MEL 200 P
Number of patients 43 162
Number of centers 1 54
Age at transplant, median
(range), yr
62 (46-69) 61 (41-69)
18-59 9 (21) 56 (35) .17
60-64 17 (40) 61 (38)
65-70 17 (40) 45 (28)
Gender
Male 24 (56) 91 (56) .97
Female 19 (44) 71 (44)
KPS at transplant
80 11 (26) 40 (25) 1
90-100 32 (74) 122 (75)
Isotype
IgG 26 (60) 100 (62) .86
IgA 8 (19) 32 (20)
Light chain 7 (16) 27 (17)
IgD 1 (2) 1 (<1)
Nonsecretory 1 (2) 2 (1)
International stage at transplant
Stage I 16 (37) 51 (31) .74
Stage II/III 20 (47) 79 (53)
Unknown 7 (16) 25 (15)
Mayo risk stratiﬁcation at
diagnosis (mSMART)
Standard risk 17 (40) 127 (78) <.0001
High risk 4 (9) 18 (11)
Unknown 22 (51) 17 (10)
Number of chemotherapy sessions
1 20 (47) 108 (67) .02
>1 23 (53) 54 (33)
Disease status before AHSCT
CR 3 (7) 33 (20) .19
VGPR 15 (35) 43 (27)
PR 23 (53) 72 (44)
Stable disease 1 (2) 11 (7)
Relapse/progression 1 (2) 3 (2)
Median follow-up of survivors
(range), mo
25 (2-50) 35 (3-50)
Values are number of cases with percents in parentheses, unless otherwise
noted.
Figure 1. PFS in BUMELVEL versus high-dose MEL.
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BUMELVEL cohort remained progression free in comparison
with 77% of MEL 200 recipients (P ¼ .02) (Figure 1). OS was
similar between both cohorts (93% versus 93% at 1 year;
P ¼ .89) (Figure 2). Cumulative incidence of relapse at 1 year
was lower in the BUMELVEL group versus MEL 200 (10%
versus 21%; P ¼ .047). Neutrophil and platelet engraftment
kinetics were similar between both groups (Figures 3 and 4).
In multivariate analysis, PFS was superior in the BUMEL-
VEL cohort (hazard ratio for relapse/death, 1.87 for MEL 200
cohort; P ¼ .04). BUMELVEL therapy was not associated with
any difference in OS or relapse risk at the time of the analysis.
Patients who achieved at least a VGPR before AHSCT had a
superior PFS post-AHSCT (CR, 1.000 [95% conﬁdence interval
{CI}, 1.000 to 1.000]; VGPR, 1.983 [95% CI, .876 to 4.489]; PR,
2.668 [95% CI, 1.260 to 5.652]; and stable disease, 3.468 [95%Table 2
Response Status before and after AHSCT using BUMELVEL Regimen
Response Status Patients before AHSCT Patients after AHSCT
CR 3 (7%) 18 (42%)
VGPR 15 (35%) 12 (28%)
PR 23 (53%) 12 (28%)
Less than PR 2 (4%) 1 (2%)CI, 1.337 to 8.996]), whereas lower KPS (80) and higher
international stage were associated with inferior OS (relative
risk for OS, 2.283 [95% CI,1.093 to 4.769] for KPS 80, P¼ .02;
hazard ratio for OS, 3.568 [95% CI, 1.326 to 9.598] for stages II
to III, P ¼ .0086).
Regimen-Related Toxicity
There was no TRM in the BUMELVEL group and no epi-
sodes of SOS disease. There was a small but statistically sig-
niﬁcant TRM in the MEL cohort (relative risk for TRM, .03
[95% CI, .01 to .06]). The most common grade 3 adverse
events (Table 3) included the expected febrile neutropenia,
mucositis, and hypophosphatemia. Other adverse events
presenting in less than 10% of the patients on the BUMELVEL
group were diarrhea, nausea, hypocalcemia, transaminitis,
and hyperglycemia. The median hospital stay for the
BUMELVEL group was 19 days.
Dose Targeting of BU
The ﬁrst 2 daily infusions of BU on the BUMELVEL
regimen were given at a ﬁxed dose of 130 mg/m2 over
3 hours from days 6 to 5. This dose has been found to be
safe and equivalent to the standard daily dose of 3.2 mg/kg
[11]. The third and fourth daily doses of i.v. BU were adjusted
to yield a systemic plasma drug exposure, represented by
a targeted AUC of 5000 mM$min per dose for a total of
20,000 mM$min. Only 23% of patients had an AUC outside an
acceptable range of 5000 mM$min  20% (<4000 orFigure 2. OS in BUMELVEL versus high-dose MEL.
Figure 3. Cumulative incidences of neutrophil engraftment in BUMELVEL
versus high-dose MEL.
Table 3
BUMELVEL Toxicities per National Cancer Institute Common Terminology
Criteria for Adverse Events, version 4.03
Toxicities No. of Cases
Grade 3
Febrile neutropenia 33 (77%)
Mucositis 16 (37%)
Hypophosphatemia 8 (19%)
Diarrhea 4 (9%)
Nausea 4 (9%)
Hypocalcemia 3 (7%)
Transaminitis 3 (7%)
Hyperglycemia 2 (5%)
Grade 4
Hypocalcemia 2 (5%)
Mucositis 2 (5%)
Transaminitis 1 (2%)
T.E. Rodriguez et al. / Biol Blood Marrow Transplant 22 (2016) 1391e13961394>6000 mM$min). Doses were adjusted on days 4 and 3 to
achieve the total desired AUC of 20,000 mM$min.
DISCUSSION
High-dose chemotherapy followed by AHSCT is consid-
ered a standard approach by the International Myeloma
Working Group for transplant-eligible MM patients. The
addition of novel agents, like the immunomodulatory drugs
thalidomide, lenalidomide, and pomalidomide and the pro-
teasome inhibitors VEL and carﬁlzomib, in treatment para-
digms has led to unprecedented survival improvement in
patients with MM [12-14].
In the context of stem cell transplantation for MM, there is
a relationship between the achievement of CR or VGPR and
PFS or OS [15]. VEL-based induction regimens result in sig-
niﬁcant improvements in response, PFS, and OS compared
with non-VELebased induction regimens [16]. In our study
100% of patients in the BUMELVEL cohort received induction
with VEL combination regimens before AHSCT versus 62% of
patients in the control group. Because control subjects were
matched with patients for disease status before trans-
plantation, we believe the lack of VEL in the induction therapy
is not impacting the outcomes observed. More patients in the
control group were in CR prior to transplantation compared
with the BUMELVEL group (20% versus 7%, respectively). The
higher CR rate in the control group might be related to a
higher representation of standard-risk patients per mSMART
andmore patients with only 1 prior line of therapy pre-AHSCT
in this group.
The study group was treated before the availability of
other proteasome inhibitors. Carﬁlzomib, which was
approved by the US Food and Drug Administration in 2012Figure 4. Cumulative incidences of platelet engraftment in BUMELVEL versus
high-dose MEL.for the treatment of patients with MM who have received at
least 2 prior therapies, including VEL and an immunomod-
ulatory agent, has shown activity in patients with newly
diagnosed as well as relapsed or refractory MM [17]. In a
randomized, phase III, open-label, multicenter study for pa-
tients with relapsed or refractory MM, carﬁlzomib with
dexamethasonewas found to deliver better response and PFS
rates when compared with VEL with dexamethasone [18].
These observations suggest that carﬁlzomib-based regimens
could deliver better responses before AHSCT in comparison
with VEL-based regimens. Obviously, this will need to be
validated in prospective clinical trials while paying special
attention to therapeutic index.
Despite achievements of impressive response rates after
inductions with novel therapy regimes, AHSCT continues to
deliver improvement in PFS and OS as consolidation of these
responses [19]. A phase II study of extended treatment with
carﬁlzomib, lenalidomide, and dexamethasone (KRd) plus
AHSCT in newly diagnosed MM patients showed that this
regimen resulted in higher stringent CR rates than KRd
without AHSCT. There was also a higher rate of minimal re-
sidual disease negativity in the transplantation group [20].
The improvement in response rate after induction was
observed in our analysis where the CR plus VGPR after
BUMELVEL followed by AHSCT increased from 42% pre-
transplantation to 70% post-AHSCT. Our analysis suggests
that the novel preparative regimen BUMELVEL followed by
AHSCT is a complementary, nonredundant therapy that can
be effectively included in themanagement of MM supporting
the trends in utilization and outcomes of autologous trans-
plantation as a therapy for MM [2].
In an older study reported by Mansi et al. [21], a 46%
response rate was observed after high-dose single-agent oral
BU (16 mg/kg) followed by AHSCT in heavily pretreated pa-
tientswithMM. The absorption of oral BU is unpredictable and
may lead to unacceptable nonhematologic toxicity. We used
an i.v. BU formulation for our regimen that has been found to
deliver effective myeloablation with less nonhematologic
toxicity and higher 100-day survival compared with oral BU
[22]. Single-agent high-dose MEL 200 has been used almost
exclusively as the preferred preparative regimen for MM since
a randomized study established the superiority of this
regimen over MEL 140 mg/m2 with total body radiation [23].
There is now evidence of clonal heterogeneity and clonal
evolution throughout the natural history ofMM [24]. Based on
these observations, a response to therapy might represent the
suppression of a sensitive clone, whereas resistant clones
remain unperturbed and become proportionally more
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nale supports the development of preparative regimens
combining synergistic agents to achieve deeper responses to
circumvent the possibility of heterogeneous resistant clones
leading to relapse while maintaining an acceptable thera-
peutic index. The combination of BU with either MEL or
cyclophosphamide has been used for over 20 years as an
alternative preparative regimen in MM before AHSCT [25-28].
Proteasome inhibitors such as VEL have a consistent anti-
tumor activity against chemoresistant and chemosensitive
myeloma cells. The sensitivity of chemoresistant myeloma
cells to this chemotherapeutic agent is markedly increased
(100,000- to 1,000,000-fold) without affecting normal he-
matopoietic cells [29]. This observation allowed us to deliver
this drug 24 hours before the stem cell infusion without
potentially affecting engraftment. We did not observe graft
failure or delayed engraftment in the BUMELVEL cohort.
It has been suggested that VEL up-regulates the anti-
apoptotic protein MCL-1, and the sequence of administra-
tion may be critical to the combination of VEL and MEL 200
[30]. Doses of VEL were escalated from 1.0 mg/m2 up to
1.6 mg/m2. The increase in apoptosis on samples obtained
from patients who were treated with MEL followed by VEL
was superior to the apoptosis observed with VEL preceding
MEL [31]. The combination of MEL and VEL has been found to
be effective in the relapse setting as well [32,33].
Nishihori et al. [34] completed a phase I/II study of VEL in
combination with MEL followed by tandem autologous
transplants in primary refractory MM patients. However,
with the availability of new potent novel agents, the role of
tandem transplantation in patients with MM is in question.
Our novel combination of BUMELVEL delivered an
impressive overall response rate of 98%, including at least a
VGPR of 70% and a CR rate of 42%. These responses compare
favorably with reported responses using single-agent MEL
200 (20% to 40% CR and 40% to 55% CR/VGPR) [15]. The pri-
mary endpoint of the study, 1-year PFS, was signiﬁcantly
improved in the BUMELVEL cohort in comparison with
single-agent MEL 200 (90% versus 77%, respectively; P¼ .02).
The improvement in PFS was achieved despite a higher
proportion of standard-risk patients in the control group in
comparison with the BUMELVEL cohort by mSMART criteria
and more patients with >1 prior line of therapy pre-AHSCT
in the BUMELVEL group. OS was similar between the 2
groups, probably due to the relatively short median duration
of follow-up and the multitude of treatment options avail-
able in relapsed MM. The main adverse events were
manageable and included neutropenic fever, mucositis, and
hypophosphatemia. Adverse events did not translate into
transplant-related mortality. The incidence of febrile neu-
tropenia (77%) is similar to that reported by Lahuerta using
BU and MEL [21]. Among recipients of high-dose chemo-
therapy in high-risk protocols (eg, BU, cyclophosphamide,
etoposide), severe mucositis is reported in excess of 60% to
90% [35]. In our study only 37% and 2% of patients developed
grade 3 and grade 4 mucositis, respectively. Thus, collec-
tively, the addition of VEL to BUMEL does not appear to in-
crease adverse events. The lower incidence of adverse events
may be due to the use of a targeted dose of BU and the
incorporation of palifermin as a mucoprotectant.
Engraftment was prompt and predictable and was not
different from historical control subjects with single-agent
MEL 200. Moreover, the once-daily dosing of BU allowed us
to perform outpatient transplantation using the BUMELVEL
regimen.Our analysis has the limitations of being a case-control
retrospective comparison with a registry population. This
type of analysis could potentially introduce a selection bias
through center effects. However, no center effect has ever
been identiﬁed in autologous transplant studies for MM in
the CIBMTR. The improvement in PFS observed in the
BUMELVEL cohort could be related to the targeted BU ther-
apy used in this regimen, the synergism observed in prior
studies between MEL and VEL, or both. Randomized pro-
spective clinical trials would probably help in answering
these questions.
In conclusion, pharmacokinetic-directed dosing of BU can
be safely combined with MEL 140 mg/m2 and VEL 1.6 mg/m2
(BUMELVEL) without adding nonhematologic toxicity or
transplant-related mortality. This novel regimen delivered
high response rates and a better PFS comparedwithMEL 200
and warrants further study in a prospective randomized
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